Patents by Inventor George Ross Francis

George Ross Francis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIK4CA as modifier of the Rac pathway and methods of use
    Patent number: 8481269
    Abstract: Human PIK4CA genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of PIK4CA are provided.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: July 9, 2013
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Lynn Margaret Bjerke, Timothy S. Heuer
  • MELKS as modifiers of the Rac pathway and methods of use
    Patent number: 8067181
    Abstract: Human MELK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MELK are provided.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa Kadyk, George Ross Francis, Kim Lickteig, Timothy S. Heuer
  • MAPKs as modifiers of the rac, axin, and beta-catenin pathways and methods of use
    Patent number: 8067180
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, III, Michael R. Costa, Kim Lickteig
  • KIFS as Modifiers of the RHO Pathway and Methods of Use
    Publication number: 20110111402
    Abstract: Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided.
    Type: Application
    Filed: September 24, 2010
    Publication date: May 12, 2011
    Applicant: EXELIXIS INC.
    Inventors: Joanne ADAMKEWICZ, Craig D. AMUNDSEN, Lynn Margaret BJERKE, George Ross FRANCIS, Timothy S. HEUER, Kim LICKTEIG, Monique NICOLL
  • CSNKS As Modifiers of the RAC Pathway and Methods of Use
    Publication number: 20110033853
    Abstract: Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided.
    Type: Application
    Filed: May 5, 2010
    Publication date: February 10, 2011
    Applicant: EXELIXIS, INC.
    Inventors: LISA C. KADYK, GEORGE ROSS FRANCIS, LYNN MARGARET BJERKE
  • Kifs as Modifiers of the Rho Pathway and Methods of Use
    Publication number: 20090004180
    Abstract: Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided.
    Type: Application
    Filed: November 9, 2006
    Publication date: January 1, 2009
    Applicant: Exelixis Inc.
    Inventors: Joanne Adamkewicz, Craig D. Amundsen, Lynn Margaret Bjerke, George Ross Francis, Timothy S. Heuer, Kim Lickteig, Monique Nicoll
  • Melks as Modifiers of the Rac Pathway and Methods of Use
    Publication number: 20080293044
    Abstract: Human MELK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MELK are provided.
    Type: Application
    Filed: August 12, 2004
    Publication date: November 27, 2008
    Inventors: Lisa Kadyk, George Ross Francis, Kim Lickteig, Timothy S. Heuer
  • Pik4ca As Modifier of the Rac Pathway and Methods of Use
    Publication number: 20080263684
    Abstract: Human PIK4CA genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of PIK4CA are provided.
    Type: Application
    Filed: September 15, 2005
    Publication date: October 23, 2008
    Applicant: EXELIXIS INC.
    Inventors: Lisa C. Kadyk, George Ross Francis, Lynn Margaret Bjerke, Timothy S. Heuer
  • Mapks as Modifiers of the Rac, Axin, and Beta-Catenin Pathways and Methods of Use
    Publication number: 20080229435
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Application
    Filed: November 24, 2003
    Publication date: September 18, 2008
    Applicant: EX-ELIXIS, INC
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, Michael R. Costa, Kim Lickteig
  • Presenilin enhancers assays
    Patent number: 7125687
    Abstract: The invention provides methods and compositions relating to pen polypeptides having pen-specific structure and activity, related polynucleotides and modulators of pen function. The invention provides isolated pen hybridization probes and primers capable of specifically hybridizing with natural pen genes, pen-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for pen transcripts), therapy (e.g. pen inhibitors to modulate APP processing) and in the biopharmaceutical industry (e.g. as immunogens, reagents for screening chemical libraries for lead pharmacological agents, etc.).
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: October 24, 2006
    Assignee: Exelixis, Inc.
    Inventors: Daniel Tim Curtis, George Ross Francis, Michael Christopher Ellis, David Andrew Ruddy, Sharmon Monique Nicoll, Garth Joseph McGrath